David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Netflix
NFLX
|
+$751M |
| 2 |
Advanced Micro Devices
AMD
|
+$751M |
| 3 |
Micron Technology
MU
|
+$426M |
| 4 |
Chipotle Mexican Grill
CMG
|
+$363M |
| 5 |
ExxonMobil
XOM
|
+$356M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$546M |
| 2 |
ATVI
Activision Blizzard
ATVI
|
+$485M |
| 3 |
VMW
VMware, Inc
VMW
|
+$393M |
| 4 |
Microsoft
MSFT
|
+$336M |
| 5 |
UnitedHealth
UNH
|
+$303M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.03% |
| 2 | Consumer Discretionary | 9.51% |
| 3 | Healthcare | 5.77% |
| 4 | Financials | 5.47% |
| 5 | Communication Services | 4.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
551
Teradyne
TER
$56.9B
| $37.1M | 0.03% |
342,219
-480,813
| -58% | -$45.6M |
|
552
PTC Therapeutics
PTCT
$5.87B
| $37.1M | 0.03% |
1,346,967
+506,158
| +60% | +$11.6M |
|
553
CALL
United Airlines
UAL
$36.6B
| $36.9M | 0.03% |
894,900
+400,800
| +81% | +$15.8M |
|
554
Ollie's Bargain Outlet
OLLI
$4.59B
| $36.9M | 0.03% |
486,430
+264,655
| +119% | +$19.9M |
|
|
WBA
555
CALL
DELISTED
Walgreens Boots Alliance
WBA
| $36.7M | 0.03% |
1,406,100
+623,000
| +80% | +$13.9M |
|
|
ITCI
556
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $36.6M | 0.03% |
511,550
-229,827
| -31% | -$13.2M |
|
|
X
557
PUT
DELISTED
US Steel
X
| $36.3M | 0.03% |
747,000
-398,100
| -35% | -$14.5M |
|
|
RBCP
558
DELISTED
RBC Bearings Incorporated 5.00% Series A Mandatory Convertible Preferred Stock
RBCP
| $36.3M | 0.03% |
280,000
| – | – |
|
559
CALL
American Express
AXP
$229B
| $36M | 0.03% |
192,400
+66,800
| +53% | +$10.8M |
|
560
Moderna
MRNA
$55.6B
| $36M | 0.03% |
362,177
+303,845
| +521% | +$25.6M |
|
561
Marriott Vacations Worldwide
VAC
$3.82B
| $35.9M | 0.03% |
423,408
+260,776
| +160% | +$22.3M |
|
562
CALL
SoFi Technologies
SOFI
$23.8B
| $35.7M | 0.03% |
3,584,800
+332,300
| +10% | +$2.64M |
|
|
MDRX
563
DELISTED
Veradigm Inc. Common Stock
MDRX
| $35.7M | 0.03% |
3,398,754
-235,484
| -6% | -$2.89M |
|
564
PUT
Chewy
CHWY
$10B
| $35.6M | 0.03% |
1,504,900
+658,900
| +78% | +$13M |
|
565
Colgate-Palmolive
CL
$73.1B
| $35.4M | 0.03% |
444,709
-515,507
| -54% | -$38.8M |
|
566
CALL
Manulife Financial
MFC
$70.5B
| $35.4M | 0.03% |
1,604,100
+873,900
| +120% | +$16.8M |
|
567
CALL
Synopsys
SNPS
$74.9B
| $35.2M | 0.03% |
68,400
+41,400
| +153% | +$21.2M |
|
568
Outfront Media
OUT
$5.28B
| $34.9M | 0.03% |
2,539,938
+521,474
| +26% | +$5.89M |
|
569
PUT
Costco
COST
$430B
| $34.7M | 0.03% |
52,500
-300
| -0.6% | -$178K |
|
|
TGI
570
DELISTED
Triumph Group
TGI
| $34.5M | 0.03% |
2,082,631
+983,532
| +89% | +$9.97M |
|
571
PUT
Oracle
ORCL
$413B
| $34.5M | 0.03% |
327,100
-297,500
| -48% | -$32.5M |
|
572
Myriad Genetics
MYGN
$290M
| $34.5M | 0.03% |
1,801,306
-376,619
| -17% | -$6.52M |
|
|
NUVL
573
DELISTED
Nuvalent
NUVL
| $34.5M | 0.03% |
468,183
+150,907
| +48% | +$9.34M |
|
574
NETSCOUT
NTCT
$2.75B
| $34.4M | 0.03% |
1,565,484
+321,802
| +26% | +$7.22M |
|
575
Sarepta Therapeutics
SRPT
$1.93B
| $34.3M | 0.03% |
355,533
+263,375
| +286% | +$25.3M |
|
Similar funds
David Shaw's Q4 2023 Portfolio in Review
As of Q4 2023, David Shaw held 4,806 positions worth $114B, up 19% from $95.8B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
David Shaw's Q4 2023 filing shows 575 new, 1,549 increased, 1,464 reduced and 527 closed positions. Its largest new stake was iShares iBoxx $ High Yield Corporate Bond ETF: 2,424,593 shares worth $188M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $546M.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 17% a quarter earlier, followed by Consumer Discretionary and Healthcare.
- David Shaw's largest Q4 2023 buy was iShares iBoxx $ High Yield Corporate Bond ETF: 2,424,593 shares worth $188M.
- David Shaw added most to Netflix in Q4 2023, an estimated $751M increase.
- David Shaw's biggest Q4 2023 reduction was Microsoft, cutting an estimated $336M.
- David Shaw fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2023, selling an estimated $546M.
- David Shaw's ten largest holdings make up 12% of its $114B portfolio in Q4 2023.
- David Shaw opened 575 new positions and closed 527 in Q4 2023.
- David Shaw's portfolio value rose 19% quarter-over-quarter to $114B.
Based on D.E. Shaw & Co's 13F filing for Q4 2023, filed 14 Feb 2024.